🇺🇸 FDA
Patent

US 9878033

Immunogenic peptides for treatment of herpes simplex virus infection and conditions

granted A61KA61K2039/55561A61K2039/57

Quick answer

US patent 9878033 (Immunogenic peptides for treatment of herpes simplex virus infection and conditions) held by The Regents of the University of California expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/55561, A61K2039/57, A61K39/12, A61K39/245